Benazepril was effective and safe for advanced chronic kidney disease without diabetes: COMMENTARY

Hsu, Chi-yuan
July 2006
ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p19
Academic Journal
The article presents the author's views on a study, which focuses on the efficacy and safety of benazepril for advanced chronic renal insufficiency. He informs that the use of angiotensin-converting enzyme (ACT) inhibitors is often found to retard chronic kidney disease (CKD) progression. Studies found that ACE inhibitors are safe and effective in patients with advanced CKD. However, studies carried out in North America or Europe did not bring good results and so appropriate application of proven effective therapies to retard progression of CKD will be necessary.


Related Articles

  • Benazepril was effective and safe for advanced chronic kidney disease without diabetes.  // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p19 

    The article presents information on a study, which focuses on the efficacy and safety of benazepril for advanced chronic renal insufficiency. The study was mainly concentrated on 224 patients with 18 to 70 years of age in a hospital in Guangzhou, China. The controlled group of the study were...

  • Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Morita, Satoshi; Fukuhara, Shunichi; Akizawa, Tadao; Asano, Yasushi; Kurokawa, Kiyoshi // Clinical & Experimental Nephrology;Sep2005, Vol. 9 Issue 3, p219 

    Background. The number of patients with chronic kidney disease (CKD) in Japan is currently rising. Therefore, measures to control the progression of CKD from a predialysis condition to endstage renal failure are urgently required. We are conducting a clinical trial to investigate the efficacy of...

  • Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Zucchelli, Pietro; Zuccala, Alessandro; Borghi, Marcello; Fusaroli, Maurizio; Sasdelli, Mauro; Stallone, Carmine; Sanna, Giovanni; Gaggi, Rossella // Kidney International;Aug1992, Vol. 42 Issue 2, p452 

    Long term comparison between captopril and nifedipine in the progression of renal insufficiency. To verify the hypothesis that angiotensin-converting enzyme (ACE) inhibitors possess a unique renoprotective effect in progressive chronic renal disease, we decided to compare the effects of an ACE...

  • End-stage renal disease: Magnitude of the problem, prognosis of future trends and possible solutions. Port, Friedrich K. // Kidney International Supplement;Aug1995, Issue 50, pS-3 

    The incidence rate per million population of treated end-stage renal disease (ESRD) has been increasing at similar rates in most countries that record counts of new ESRD patients per year. Data from the United States Renal Data System (USRDS) suggest an exponential growth for both incidence...

  • NPHS2mutation associated with recurrence of proteinuria after transplantation. Billing, Heiko; Müller, Dominik; Ruf, Rainer; Lichtenberger, Anne; Hildebrandt, Friedhelm; August, Christian; Querfeld, Uwe; Haffner, Dieter // Pediatric Nephrology;May2004, Vol. 19 Issue 5, p561 

    Mutations in the NPHS2 gene encoding podocin are associated with steroid-resistant nephrotic syndrome (SRNS) in childhood. Patients usually present with focal segmental glomerulosclerosis (FSGS). It is unclear to what extent SRNS due to NPHS2 mutations predisposes to recurrence of...

  • Slowing the progression of chronic renal insufficiency. Tonelli, Marcello; Gill, John; Pandeya, Sanjaya; Bohm, Clara; Levin, Adeera; Kiberd, Bryce A. // CMAJ: Canadian Medical Association Journal;4/2/2002, Vol. 166 Issue 7, p906 

    Discusses a study of patients with chronic renal insufficiency (CRI) in Canada to investigate the use of strategies which delay or prevent progression of the disease. Strategies which include aggressive control of blood pressure and use of angiotensin-converting enzyme (ACE) inhibitors;...

  • No impact of hyperkalaemia with renin–angiotensin system blockades in maintenance haemodialysis patients. Sang-Woong Han; Young-Woong Won; Joo-Hark Yi; Ho-Jung Kim // Nephrology Dialysis Transplantation;Apr2007, Vol. 22 Issue 4, p1150 

    Background. Renin–angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated...

  • Angiotensin-Converting Enzyme Inhibition and Chronic Kidney Disease: Does Proteinuria Matter? Joshi, Amit J.; Levine, Jerrold S. // Kidney;Sep/Oct2007, Vol. 16 Issue 5, p204 

    The article discusses the mechanisms by which proteinuria may induce renal injury and the potential of angiotensin-converting enzyme inhibitors (ACEIs) to delay the progression of chronic kidney disease (CKD) in the U.S. It is shown that interventions that reduce proteinuria delay CKD...

  • Acute phosphate nephropathy. Markowitz, Glen S.; Perazella, Mark A. // Kidney International;Nov2009, Vol. 76 Issue 10, p1027 

    Acute phosphate nephropathy (APhN) is a clinical pathological entity characterized by acute and subsequent chronic renal failure following exposure to oral sodium phosphate (OSP) bowel purgatives. Renal biopsy findings include acute and chronic tubular injury with prominent tubular and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics